Chattip Prueksapraopong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Chattip Prueksapraopong has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Donald Barry Kohn
University of California, Los Angeles, Los Angeles, California, UNITED STATES
2 shared publications Ami J. Shah
Division of Pediatric Hematology/ Oncology/ Stem cell transplantation and Regenerative Medicine, Stanford school of medicine, Palo Alto, CA, United States
1 shared publicationAugustine Fernandes
Department of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine, University of California, Los Angeles, CA, USA, United States
1 shared publicationBeatriz Campo Fernandez
Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, Los Angeles, CA, Los Angeles, California, United States
1 shared publication- Bruce R. Blazar
University of Minnesota
1 shared publication Bruck Habtemariam
David Geffen School of Medicine, University of California, Los Angeles, CA, USA, Los Angeles, California, United States
1 shared publication
Latest Publications
- Open Access
- 23 June 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (16) , 5741
Response to "Defining durability in SCD gene therapy"
- 23 June 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (16) , 5741
Open AccessResponse to "Defining durability in SCD gene therapy"
- Open Access
- 20 April 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (14) , 4991-5002
Clinical Outcomes of Lentiviral Vector Gene Therapy for Sickle Cell Disease
Sickle cell disease (SCD) is a monogenic disorder where autologous gene therapy may offer a safer curative alternative to allogeneic transplantation. We report outcomes from a Phase I/II study using the Lenti/G-βAS3-FB lentiviral vector, encoding an anti-sickling β-globin. This trial was registered at ClinicalTrials.gov (NCT02247843). This single-site study treated four adults with severe SCD. The first patient was treated using the original Lenti/βAS3-FB and initial protocol, which resulted in suboptimal clinical response. Subsequent protocol refinements included improved hematopoietic stem and progenitor cell (HSPC) collection using plerixafor-mobilized peripheral blood apheresis with pre-collection erythrocytapheresis, and use of an optimized lentiviral vector with a transduction enhancer. All patients received myeloablative busulfan conditioning followed by infusion of gene-modified autologous HSPCs. Primary endpoints were safety and feasibility; secondary endpoints included gene marking, therapeutic hemoglobin expression, and clinical outcomes. All patients achieved hematopoietic recovery without rescue transplantation. The first patient demonstrated low gene marking (peak vector copy number [VCN] 0.035) and undetectable HbAS3 expression, with minimal clinical benefit. In contrast, the three patients treated with the optimized protocol achieved higher and sustained gene marking (peak granulocyte VCNs ~0.5-2.0) and persistent HbAS3 expression. These patients experienced some reductions in vaso-occlusive crises and transfusion requirements, with two becoming transfusion-independent. No insertional oncogenesis was observed. This trial highlights the necessity of optimized vector design and transduction protocols to achieve durable gene expression. While this specific vector will not be pursued further, the study provides crucial insights into gene therapy protocol development.
- 20 April 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (14) , 4991-5002
Open AccessClinical Outcomes of Lentiviral Vector Gene Therapy for Sickle Cell Disease
Sickle cell disease (SCD) is a monogenic disorder where autologous gene therapy may offer a safer curative alternative to allogeneic transplantation. We report outcomes from a Phase I/II study using the Lenti/G-βAS3-FB lentiviral vector, encoding an anti-sickling β-globin. This trial was registered at ClinicalTrials.gov (NCT02247843). This single-site study treated four adults with severe SCD. The first patient was treated using the original Lenti/βAS3-FB and initial protocol, which resulted in suboptimal clinical response. Subsequent protocol refinements included improved hematopoietic stem and progenitor cell (HSPC) collection using plerixafor-mobilized peripheral blood apheresis with pre-collection erythrocytapheresis, and use of an optimized lentiviral vector with a transduction enhancer. All patients received myeloablative busulfan conditioning followed by infusion of gene-modified autologous HSPCs. Primary endpoints were safety and feasibility; secondary endpoints included gene marking, therapeutic hemoglobin expression, and clinical outcomes. All patients achieved hematopoietic recovery without rescue transplantation. The first patient demonstrated low gene marking (peak vector copy number [VCN] 0.035) and undetectable HbAS3 expression, with minimal clinical benefit. In contrast, the three patients treated with the optimized protocol achieved higher and sustained gene marking (peak granulocyte VCNs ~0.5-2.0) and persistent HbAS3 expression. These patients experienced some reductions in vaso-occlusive crises and transfusion requirements, with two becoming transfusion-independent. No insertional oncogenesis was observed. This trial highlights the necessity of optimized vector design and transduction protocols to achieve durable gene expression. While this specific vector will not be pursued further, the study provides crucial insights into gene therapy protocol development.
- 2 July 2019
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 49 (10) , 924-931
Post transplant cyclophosphamide based haplo-identical transplant versus umbilical cord blood transplant; a meta-analysis
Objectives: Both haplo-identical transplant (haplo) and umbilical cord transplant (UC) are valuable graft options for patients without available matched relative. Previous studies showed inconsistent outcomes comparing Post transplant Cyclophosphamide based haplo (PTCy-haplo) and UC; therefore, we attempt to compare the studies by mean of meta-analysis. Methods: We searched for titles of articles in MEDLINE (PubMed), Cochrane library, EMBASE database and Google scholar that compared transplantation with PTCy-haplo versus UC. We conducted a random-effect meta-analysis of seven studies involving a total of 3434 participants and reported the pooled odd ratios (OR) of acute graft-versus-host disease (aGVHD), chronic graft-versus-host disease (cGVHD), relapse and overall survival (OS) between PTCy-haplo and UC groups. Results: We found a significantly decreased risk of aGVHD and relapse in the PTCy-haplo group compared to the UC group with a pooled OR of 0.78, 95% Confidence Interval (CI) 0.67-0.92, I2=0%, and 0.74, 95% CI 0.57–0.97, I2=23.9% respectively. We also found a significantly increased rate of cGVHD and OS with a pooled OR of 1.41, 95% CI 1.02–1.95, I2=56.8%, and 1.77, 95% CI 1.1–2.87, I2=82.5%, respectively. Conclusion: Our meta-analysis of clinical trials demonstrated superior outcome from PTCy-haplo group compared to the UC group in terms of decreased rate of aGVHD and relapse as well as the increased rate of OS but inferior in terms of increased cGVHD risk compared to UC transplant.
- 2 July 2019
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 49 (10) , 924-931
Post transplant cyclophosphamide based haplo-identical transplant versus umbilical cord blood transplant; a meta-analysis
Objectives: Both haplo-identical transplant (haplo) and umbilical cord transplant (UC) are valuable graft options for patients without available matched relative. Previous studies showed inconsistent outcomes comparing Post transplant Cyclophosphamide based haplo (PTCy-haplo) and UC; therefore, we attempt to compare the studies by mean of meta-analysis. Methods: We searched for titles of articles in MEDLINE (PubMed), Cochrane library, EMBASE database and Google scholar that compared transplantation with PTCy-haplo versus UC. We conducted a random-effect meta-analysis of seven studies involving a total of 3434 participants and reported the pooled odd ratios (OR) of acute graft-versus-host disease (aGVHD), chronic graft-versus-host disease (cGVHD), relapse and overall survival (OS) between PTCy-haplo and UC groups. Results: We found a significantly decreased risk of aGVHD and relapse in the PTCy-haplo group compared to the UC group with a pooled OR of 0.78, 95% Confidence Interval (CI) 0.67-0.92, I2=0%, and 0.74, 95% CI 0.57–0.97, I2=23.9% respectively. We also found a significantly increased rate of cGVHD and OS with a pooled OR of 1.41, 95% CI 1.02–1.95, I2=56.8%, and 1.77, 95% CI 1.1–2.87, I2=82.5%, respectively. Conclusion: Our meta-analysis of clinical trials demonstrated superior outcome from PTCy-haplo group compared to the UC group in terms of decreased rate of aGVHD and relapse as well as the increased rate of OS but inferior in terms of increased cGVHD risk compared to UC transplant.